Search results
Added:
1 year ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to…
View more
Added:
10 months ago
ADA 25 - PATHWEIGH roadmap for implementing weight management into primary care eliminated a population weight gain trajectory.Dr Leigh Perreault (University of Colorado Anschutz Medical Campus, US) joins us remotely to discuss the PATHWEIGH trial, which investigated a process of care to facilitate and prioritize weight management in a primary care setting. PATHWEIGH focused on reducing excess…
View more
Added:
11 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Conduction System Pacing: A Fresh Look
Start date:
Nov 13, 2024
Broadcast
Added:
1 year ago
LINC 2025 - 36-month outcomes of the Aspirex endovascular thrombectomy system for patients with acute iliofemoral deep vein thrombosis (DVT) show great efficacy with low rates of major adverse events, perioperative death, and complication.Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, Arnsberg, DE) joins us to discuss the findings from the multi-centre, post-market, follow-up study in…
View more
Added:
1 year ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary…
View more
Added:
10 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an…
View more
Added:
2 years ago
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF Trial.PROACTIVE-HF is a prospective, multicenter, open-label single arm trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 529 New-York Heart Association (NYHA) class III heart failure…
View more
Added:
6 months ago
TCT 2025 - Sub-anlysis findings showed positive safety and efficacy outcomes of the PASCAL Precision system in degenerative mitral regurgitation (DMR) patients.Dr P. Kasi Ramanathan (Promedica Toledo Hospital, OH, US) joins us on-site at TCT 2025 to share the findings from a sub-analysis looking at the affect of implant location and leaflet lesion location on the safety and effectiveness of the…
View more
Added:
11 months ago
EuroPCR 25 - First-in-human outcomes from the TRiCares Topaz Tricuspid Valve Replacement System in patents with tricuspid regurgitation (TR) show positive performance results and improved safety.We are joined by Dr Julien Dreyfus (Centre Cardiologique du Nord, Saint-Denis, FR) to discuss outcomes from the first-in-human, pivotal, multi-centre TRICURE EU study (NCT06581471; TRiCares) investigating…
View more